Background. Although mucosal leishmaniasis is a prominent disease, it has been studied only to a limited extent. It is classically treated with parenteral antimony or, as a last resort, amphotericin B.
Mucosal leishmaniasis is the sequel to cutaneous leishmaniasis in perhaps 1%-5% of infections by New World Leishmania species, such as Leishmania braziliensis [1] . Although the disease is relatively uncommon, its morbidity, coupled with the difficulty in effecting a cure, make it an important subject for antileishmanial chemotherapy.
The disease almost always involves the nasal mucosa [1] , but it can progress to involve the nasal septum, which can become perforated, as well as the palate, larynx, and pharynx. The consequent facial disfigurement and difficulty in eating and speaking create considerable morbidity and social isolation.
Although cure of the leishmaniases correlates with
Th1 cell-mediated immunity [2] , and mucosal leishmaniasis presents with high levels of cellular immunity [3] and few parasites, self-cure of mucosal leishmaniasis is so uncommon as to be reportable [4] . Standard treatment is with the classic antileishmanial agent, parenteral pentavalent antimony, at a dose of 20 mg/kg/day for 28 days [5] . Treatment for those who experience failure of antimony therapy is not standardized, although a course of intravenous amphotericin B (1 g [20 mg]/kg over 40 days) is often used. Miltefosine (Impavido [Zentaris] ) is the first oral agent to successfully treat visceral leishmaniasis. The cure rate in Indian cases of visceral leishmaniasis with a regimen of 2.5 mg/kg/day for 4 weeks was ∼95% [6, 7] . In an attempt to extend the indication to include New World cutaneous disease, we performed a large, placebo-controlled study of miltefosine (2.5 mg/kg/day orally for 28 days). In regions in Colombia in which Leishmania panamensis is endemic, the per-protocol cure rate for miltefosine was 91% (vs. 38% for placebo), but in regions of Guatemala in which combined L. braziliensis and Leishmania mexicana are found, the per-protocol cure rate was 53% (vs. 21% for placebo) [8] . The historical cure rate with antimony in both locales is у90%. The need for an oral agent for mucosal disease, and the possibility that L. braziliensis in Guatemala is unusual in its limited response to miltefosine, led us to study miltefosine for the treatment of mucosal leishmaniasis due to L. braziliensis in Bolivia.
PATIENTS AND METHODS
Original study design. The initial study design was a randomized equivalency study of oral miltefosine (50 patients) versus standard therapy with pentavalent antimony (25 patients) in the treatment of Bolivian mucosal leishmaniasis. After treatment, patients were observed after 2, 6, 9, and 12 months.
Final study design. On visiting the study site at Palos Blancos, Bolivia, the study team became aware that pentavalent antimony therapy had been rejected because it was determined to be ineffective treatment for mucosal leishmaniasis. Short courses of amphotericin B had also been rejected, such that standard therapy at the site was 45 mg/kg of amphotericin B(1 mg/kg amphotericin B every other day for a total of 45 injections over 3 months). The study protocol was, therefore, modified to compare oral miltefosine (50 patients) with intravenous amphotericin B (25 patients).
Just prior to and immediately after the availability of miltefosine, 19 patients were treated with the 45 mg/kg regimen of amphotericin B. When the efficacy of oral miltefosine became apparent in initial patients, additional patients refused to be entered into the amphotericin B arm of the study. Repeated requests over the ensuing months to enter a control group of more patients receiving amphotericin B or antimony were rejected by the patients and their physicians. Therefore, the final study design became an evaluation of 1 cohort of 78 patients who received miltefosine (2.5 mg/kg/day for 28 days). An almost contemporary group of the 19 patients who received amphotericin B (45 mg/kg) is also reported herein.
Study site. Palos Blancos is situated in a valley 400 m above sea level and 240 km (10 h by automobile) northwest of La Paz, the capital of Bolivia. Our study patients lived in the provinces of Beni or La Paz and were treated at the community clinic. The ear-nose-throat physician for this trial traveled to the site from La Paz every 1-2 months.
Study subjects. Patients were 112 years of age, and were both male and female. Clinical disease was defined as mild if it involved the nasal skin and/or nasal mucosa and extensive if it involved the palate, pharynx, and larynx. At each site, involvement consisted of erythema, fluctuant edema, firm infiltration, or erosion.
A scar signifying previous cutaneous leishmaniasis was necessary for diagnosis of mucosal leishmaniasis. Previous treatment for mucosal symptoms was permitted if the treatment was terminated 16 months before entry into this study and if symptoms had been progressing in the last 3 months. Patients were excluded from the study if they had concomitant disease, as ascertained by clinical examination and laboratory tests: complete blood count, liver function tests (aspartate aminotransferase and alkaline phosphatase measurements), and blood urea nitrogen measurement. Women of childbearing age were required to practice reproductive contraception for 4 months after initiating miltefosine therapy.
Parasitological analyses. Before treatment, 1 lesion on each patient was aspirated to visualize parasites via Giemsa staining. If no parasites were visualized, a second and, if necessary, a third aspiration was performed. If the third aspiration did not reveal parasites, a biopsy sample was obtained for staining. The aspirate was also cultured. When culture results were positive, the parasites were speciated by isoenzyme electrophoresis [9] . For patients for whom aspiration and biopsy yielded negative results, parasitological diagnosis was based on a positive leishmanin skin test result and the presence of a scar that signified prior cutaneous disease.
Drug treatment. Miltefosine, available in 50-mg capsules, was administered at doses of 2.5-3.3 mg/kg/day for 28 days, with meals. If 2 capsules were taken, 1 capsule was administered with breakfast and 1 capsule with dinner. If 3 capsules were taken, 1 capsule each was taken with breakfast, lunch, and dinner.
Patients who were treated with amphotericin B received 1 mg of amphotericin B/kg intravenously every other day, for 45 injections. Because of the lack of clinical response, 3 patients received 15 additional injections, for a total of 60 injections.
Evaluation of tolerance. Twice a week during therapy, patients receiving miltefosine were asked specifically about nausea, vomiting or diarrhea, motion sickness, arthritis or myalgias, and skin conditions, and nonspecifically about any other adverse events that they may have observed or experienced. At the end of therapy, screening laboratory tests (complete blood count and measurement of aspartate aminotransferase, alkaline phosphatase, and blood urea nitrogen levels) were repeated.
Evaluation of efficacy. The ear-nose-throat specialist examined the nasal and oral mucosa of each patient at the beginning of therapy, the end of therapy, and at 2, 6, 9, and 12 months after the end of therapy. Each site (nasal skin, nasal mucosa, palate, pharynx, and larynx) was evaluated for erythema, edema, infiltration, and erosion; each of these signs of disease was graded on a 4-point scale (0, none; 1, mild; 2, moderate; and 3, severe).
Although the study protocol indicated that each lesion would be individually used for efficacy analysis, the complexity of analyzing data from each of 5 anatomic sites at each of 6 time points for 78 patients led us to retrospectively create a composite end point (the "mucosal severity score"), consisting of the sum of the grades for all lesion sites. At any time point, the maximum mucosal severity score with which a patient could present was 60: 3 points for each of 4 pathological signs (erythema, edema, infiltration, and erosion) at each of the 5 sites (nasal skin, nasal mucosa, palate, pharynx, and larynx). Larger mucosal severity scores reflect an increased severity of involvement, an increased number of signs of involvement, and an increased number of sites of disease. The protocol-defined outcomes were clinical cure (190% loss of presenting signs), clinical improvement (50%-90% loss of presenting signs), no clinical change (25% worsening to 49% improvement in presenting signs), and clinically worse (125% worsening of presenting signs or relapse after initial improvement). Ethics review. This protocol was approved by the Comité de É thica, Colegio Médico (La Paz, Bolivia). 
RESULTS

Patients Receiving Miltefosine
Patient characteristics. For the 78 patients who receieved miltefosine, the mean age ‫ע(‬ SD) was 40 ‫ע‬ 16 years, the mean weight ‫ע(‬ SD) was 58 ‫ע‬ 9 kg, and the mean duration of mucosal disease ‫ע(‬ SD) was 5 ‫ע‬ 5 years. Fifty-seven patients (73%) were male. Parasites were observed in or cultured from aspirates or observed in biopsy samples for 50 patients (64%). This percentage of parasitologically positive patients is consistent with the difficulty of finding parasites in mucosal disease [10] . L. braziliensis was identified in each of the 7 cultures that multiplied sufficiently to be speciated by isoenzyme electrophoresis.
Forty patients (51%) presented with mild disease, defined as involvement only of the nasal skin and nasal mucosa. Of the 38 patients (49%) who presented with extensive disease (involving the palate, pharynx, and larynx), a few had the unusual feature of extensive disease without concomitant involvement of the nose. Two patients had pharyngeal disease alone, 2 patients presented with disease only of the palate and pharynx, 1 patient had involvement of the pharynx and larynx, and 1 patient presented solely with laryngeal disease. The mean number ‫ע(‬ SD) of clinical sites involved was 1.8 ‫ע‬ 0.9, and the mean mucosal severity score ‫ע(‬ SD) at entrance was 10 ‫ע‬ 8.1. The 72 evaluable patients (table 1) were equally divided among the group that had mild disease and the group that extensive disease (36 patients each).
Efficacy. Fifty-one (71%) of the 72 evaluable patients were "cured" by the definition of 190% diminution in the mucosal severity score. Almost all (49 [96%]) of these patients demonstrated complete resolution of their clinical signs. Two patients had mucosal severity scores that were 5% and 9%, respectively, of their initial scores at the 12-month follow-up visit. For cured patients as a group, mucosal severity scores decreased by about one-half at the end of treatment and by 85% at 2 months after therapy (table 2) . Nevertheless, it was not possible to define a degree of improvement at the 2-or 6-month followup visit that would clearly differentiate patients who would attain cure from patients who would not attain cure: 9 cured patients showed little improvement by the 2-or even the 6-month follow-up visit, but then improved such that they were considered to be cured at the 12-month follow-up visit.
Thirteen evaluable patients (18%) were classified as "improved" because of a 50%-90% diminution in their mucosal severity scores. The 67% mean diminution in the mucosal severity score by 2 months after therapy (table 2) indicates that some of these patients showed marked initial improvement but then relapsed, with an increase in the mucosal severity score at the 6-month follow-up visit (2 patients), the 9-month followup visit (2 patients), or the 12-month follow-up visit (1 patient).
Six patients (8%) exhibited "no clinical change" according to our definition of !50% diminution in the mucosal severity score, and 2 patients (3%) showed worsening by 125% (table  2) . Of these 8 patients, 6 never showed appreciable improve- ment, whereas 2 showed initial improvement but then relapsed by the 9-month or 12-month follow-up visit. Correlation of entrance characteristics with cure. (table 3) The extent of disease at presentation differentiated patients destined to attain cure from those who did not attain cure. The cure rate of mildly affected patients (whose disease was limited to the nasal skin and nasal mucosa) was 30 (83%) of 36, whereas the cure rate of patients with more extensive disease (involving the palate, pharynx, and larynx) was significantly less (21 [58%] of 36). Because the mucosal severity score increases as more anatomic sites are involved, the entrance mucosal severity score was significantly higher for patients who did not achieve cure than for those who did. The other entrance characteristicsduration of mucosal disease, age, weight, sex, presence of visualizable parasites, and surprisingly, presence of nasal septal perforation-were not different in patients who attained cure compared with those who did not.
Quality of life.
In patients who were cured, quality of life was substantially improved. For example, before-and-after photographs of patient 9 (figure 1) reveal the degree of cosmetic improvement that accompanies successful treatment of this disease. In addition to appearance, the inability to speak because of laryngeal involvement creates another barrier to social interaction. The most dramatic improvement in ability to speak was shown by patient 1. Observers were able to hear a normally vocalized phrase at a distance of no further than 1 m from this patient before therapy, but this distance increased to 6 m after therapy.
Tolerability. (Table 4 ) Miltefosine was well tolerated. Nausea, vomiting, and diarrhea were each reported by 8-17 patients, and episodes of nausea or vomiting were graded using the Common Toxicity Criteria. For vomiting, a Common Toxicity Criteria grade of 1 signifies 1 episode per day, and a grade of 2 signifies 2-5 episodes per day. For diarrhea, a grade of 1 signifies an increase of 2-3 stools per day, and grade 2 signifies an increase of 4-6 stools per day. Most episodes were grade 1; 1 episode was grade 3. Most episodes lasted 1-2 days and a few lasted 3-4 days. Mean values of liver function tests and kidney function tests did not change; a few patients had values that were slightly above the upper limit of normal after treatment.
Patients Treated with Amphotericin B
At entrance, the mean mucosal severity score was 10 (SD, ‫ע‬ 5; range, 5-23). Five patients were nonevaluable, among whom 3 discontinued treatment prematurely after 9, 17, and 18 injections because of adverse events (vomiting and/or increased creatinine levels and/or anaphylaxis). Seven of the 14 evaluable patients were cured. Their mean mucosal severity score ‫ע(‬ SD) at entrance was 11 ‫ע‬ 6. Four patients had mild disease that was limited to the nares, whereas 3 patients had more extensive disease. Seven evaluable patients were not cured. Remarkably, 5 of the these patients had disease that was limited to the nares, whereas only 2 of these patients had extensive disease. Each classification was unambiguous. The mean mucosal severity score at entrance was 8 and, at the end of the follow-up period, it was 13. Each patient who experienced clinical worsening or relapse had a higher score at the end of the follow-up period than at the beginning of the study.
DISCUSSION
Mucosal leishmaniasis is infrequently studied and poorly understood: in a search of the literature published from 1982 to 2006, we could find only 8 clinical trials, each including 10-59 patients, for a total of 238 reported patients. In our evaluation of miltefosine in 78 Bolivian patients, we were challenged by the inherent lack of knowledge about this disease.
To report the data of multiple signs at multiple sites at multiple times in these many patients, we created the mucosal severity score. The mucosal severity score is a composite end point in which 40% of the weight consists of disease of the nasal skin and nasal mucosa and 60% of the weight consists of disease of the palate, pharynx, and larynx. At each anatomic site, milder signs (i.e., erythema and edema) are weighted equally with more-severe signs (i.e., infiltration and erosion).
We prospectively defined cure as a 190% diminution in mucosal disease at 12 months after the end of therapy. On this basis, 51 (71%) of the 72 evaluable patients achieved cure, with 49 of these patients showing 100% improvement in their mucosal severity scores. The cure rate for mild disease of the nose was 30 (83%) of 36, a value that was significantly higher than the cure rate for patients with involvement of the palate, pharynx, and larynx (21 [58%] of 36).
It is difficult to determine the best controls with which to compare our data. In Rio de Janeiro, in coastal Brazil, where low doses of antimony are effective for treatment of cutaneous disease [11] , mucosal disease is also responsive to low amounts of antimony: 91% of 36 patients with mild disease experienced cure after treatment with 5 mg/kg/day of antimony for 30-45 days [10] . Because Palos Blancos is located ∼250 km from Peru, the Peruvian experience may be the most relevant to our results. Franke et al. [5] found that an antimony regimen cured 6 (75%) of 8 mildly affected patients but only 2 (10%) of 21 extensively affected patients. Llanos-Cuentas et al. [12] reported a 63%-75% cure rate for antimony, with or without the addition of allopurinol, in 59 Peruvian patients with disease involving at least 3 mucosal regions; this definition is comparable to our definition of "extensive" disease in the present study. There is, to our knowledge, only 1 previous report from Bolivia. Amphotericin B, at a total dose of ∼1.5 g, cured 9 of 10 patients when administered alone, and 8 of 10 patients when given with itraconazole [13] . The efficacy of comparator treatment at our site at Palos Blancos can be approximated by the results observed in our nonrandomized amphotericin B group, whose members entered the study just prior to those patients who were treated with miltefosine. We treated 19 patients with heroic courses of amphotericin B (45 injections of 1 mg/kg, administered every other day), who demonstrated a per-protocol cure rate of only 50% (7 of 14 patients).
The benefits of successful treatment of mucosal disease, by any agent, can be striking. The improvement in quality of life that accompanies normal facial appearance and ability to vocalize is prized by the patient and is heartwarming for the treatment team.
Ninety-two percent of Bolivian leishmaniasis is caused by L. braziliensis [14] , and each parasite that we speciated was L. braziliensis. The 83% success rate in treating mild mucosal disease due to L. braziliensis in Palos Blancos contrasts with the lower 50% success rate in treating routine cutaneous disease due to L. braziliensis in Guatemala. This difference suggests that L. braziliensis is not, in fact, 1 species of parasite, at least in terms of the important characteristic of response to antileishmanial agents. Leishmania are typically speciated on the basis of chromatographic behavior of energy metabolic enzymes, the presence of surface antigens, or PCR profile, characteristics that have an unknown correlation with clinically important attributes. Our results raise the larger issue of the extent to which clinical trial data on a species found in 1 region can be generalized to the "same" species in other regions, let alone to different species.
Miltefosine was well tolerated, as was expected. There is now considerable experience with treatment with this product for у28 days in cutaneous disease. Patients with both cutaneous and mucosal disease are systemically well, and tolerance for patients with mucosal disease should not differ from that already reported for patients with cutaneous disease.
This trial, although open-label, presents results that suggest that miltefosine, rather than antimony, should be the treatment of choice for Andean mucosal leishmaniasis. For mildly affected patients, our data and those of Franke et al. [5] indicate that most patients will achieve cure with miltefosine or antimony. For more extensive disease, our data and those of Llanos-Cuentas et al. [12] indicate that fewer patients (∼60%) will achieve cure with either miltefosine or antimony. Surprisingly, in this region, the miltefosine cure rate for both mild and extensive disease was at least as good as that for amphotericin B, the drug of last resort for all forms of leishmaniasis. Although female reproductive contraception must be strictly maintained during receipt of the drug, the tolerability of miltefosine is superior to antimony and far superior to amphotericin B. Miltefosine has the important advantage of being an oral agent for a disease that otherwise requires between 28 and 45 injections of parenteral agents.
